EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps

Claire Hopkins iD, Joaquim Mullol iD, Asif H Khan iD, Stella E Lee iD, Martin Wagenmann iD, Peter Hellings iD, Wytske Fokkens iD, Jérôme Msihid iD, Radhika Nair iD, Siddhesh Kamat iD, Scott Nash iD, Amr Radwan iD und 3 weitere

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.627 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2024. Verfasst von Claire Hopkins und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, King's College London, London, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinitis, Rhinosinusitis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the severity of the top 5 22‐item Sino‐Nasal Outcome Test (SNOT‐22) items ranked most important by patients with chronic rhinosinusitis with nasal polyps (CRSwNP), the effect of dupilumab on these items, and their association with objective disease measures. Study Design Post hoc analysis of the SINUS‐24 (NCT02912468) and SINUS‐52 (NCT02898454) clinical trials.

Setting

Multinational, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group studies.

Methods

Patients ranked the SNOT‐22 items most affecting their health at baseline. Item symptom severity (0‐5 scale) was assessed at baseline, Week 24 (W24), and Week 52 (W52). Changes in nasal polyps score (NPS) and Lund–Mackay (LMK) scores were assessed in patients with/without SNOT‐22 items improvements of at least 1 severity group point at W24 and W52.

Results

The SNOT‐22 items ranked most important at baseline were “decreased sense of smell/taste” (87% of patients), followed by “nasal blockage” (82%), “postnasal discharge” (40%), “thick nasal discharge” (37%), and “wake up at night” (26%); 82%, 61%, 32%, 40%, and 26% of patients reported severe symptoms (score 4 or 5) for these items, respectively. Dupilumab improved score severity for all top 5 items versus placebo at W24 and W52. Improvements in NPS and LMK scores were numerically greater in patients with improvements in the SNOT‐22 top 5 items.

Conclusion

Loss of smell/taste was ranked as the most important symptom by patients with CRSwNP. Dupilumab reduced the severity of the top 5 most important SNOT‐22 items versus placebo, in parallel with improvements in objective disease measures. Clinical Trial Registration SINUS‐24 and SINUS‐52 clinical trials were registered with ClinicalTrials.gov , identifiers NCT02912468 and NCT02898454, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNasal PolypsRhinitisRhinosinusitisSinusitisHumansChronic DiseaseQuality of LifeDouble-Blind Method

Stichwörter der Autor:innen

SNOT‐22chronic rhinosinusitisnasal polypssmelltaste

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, King's College London, London, UK.
  • Hospital Clínic Barcelona, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.
  • Global Medical Affairs, Sanofi, Chilly-Mazarin, France.
  • Harvard Medical School, Brigham and Women's Hospital, Division of Otolaryngology-Head & Neck Surgery, Boston, Massachusetts, USA.
  • Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany.
  • Department of Otorhinolaryngology-Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.

ORCID-Profile: Claire Hopkins, Joaquim Mullol, Asif H Khan, Stella E Lee, Martin Wagenmann, Peter Hellings, Wytske Fokkens, Jérôme Msihid, Radhika Nair, Siddhesh Kamat, Scott Nash, Amr Radwan, Juby A Jacob-Nara

Zitieren

APA

Hopkins, C., Mullol, J., Khan, A. H., Lee, S. E., Wagenmann, M., Hellings, P., Fokkens, W., Msihid, J., Nair, R., Kamat, S., Nash, S., Radwan, A., Jacob-Nara, J. A., Deniz, Y., & Rowe, P. J. (2024). Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.627

Vancouver

Hopkins C, Mullol J, Khan AH, Lee SE, Wagenmann M, Hellings P, et al. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.627

BibTeX
@article{Hopkins2024,
  author = {Hopkins, Claire and Mullol, Joaquim and Khan, Asif H and Lee, Stella E and Wagenmann, Martin and Hellings, Peter and Fokkens, Wytske and Msihid, Jérôme and Nair, Radhika and Kamat, Siddhesh and Nash, Scott and Radwan, Amr and Jacob-Nara, Juby A and Deniz, Yamo and Rowe, Paul J},
  title = {Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.627}
}
Kostenlos starten →